XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Other Intangible Assets (Tables)
3 Months Ended
Sep. 30, 2021
Goodwill and Other Intangible Assets  
Schedule of change in carrying amount of goodwill

    

Aytu BioPharma

    

Aytu Consumer Health

    

Consolidated

(In thousands)

Balance as of June 30, 2021

$

57,165

$

8,637

$

65,802

Goodwill impairment

 

(19,453)

 

 

(19,453)

Balance as of September 30, 2021

$

37,712

$

8,637

$

46,349

Schedule of finite lived intangible assets

September 30, 2021

Weighted-

Average

Gross

Net

Remaining

Carrying

Accumulated

Carrying

Life (in

    

Amount

    

Amortization

    

Impairment

    

Amount

    

years)

(In thousands)

Licensed assets

$

3,246

$

(1,546)

$

$

1,700

3.67

Acquired product technology right

 

45,400

 

(5,062)

 

 

40,338

 

12.66

Acquired technology right

30,200

(946)

29,254

16.50

Acquired product distribution rights

 

11,354

 

(2,450)

 

 

8,904

 

8.35

Acquired in-process R&D

2,600

2,600

Indefinite-lived

Acquired commercial technology

630

(335)

295

0.50

Acquired trade name

400

(106)

294

1.50

Acquired customer lists

 

390

 

(390)

 

 

 

0.00

Total

$

94,220

$

(10,835)

$

$

83,385

 

13.30

June 30, 2021

Weighted-

Average

Gross

Remaining

Carrying

Accumulated

    

Net Carrying

Life (in

    

Amount

    

Amortization

    

Amount

    

years)

(In thousands)

Licensed assets

$

3,246

$

(1,430)

$

1,816

3.92

Acquired product technology right

45,400

(4,160)

41,240

12.88

Acquired technology right

30,200

(501)

29,699

16.75

Acquired product distribution rights

11,354

(2,073)

9,281

8.57

Acquired in-process R&D

 

2,600

 

 

2,600

Indefinite-lived

Acquired commercial technology

630

(178)

452

0.75

Acquired trade name

400

(56)

344

1.75

Acquired customer lists

390

(358)

32

0.01

Total

$

94,220

$

(8,756)

$

85,464

13.47

Schedule of Indefinite lived intangible assets

September 30, 2021

Weighted-

Average

Gross

Net

Remaining

Carrying

Accumulated

Carrying

Life (in

    

Amount

    

Amortization

    

Impairment

    

Amount

    

years)

(In thousands)

Licensed assets

$

3,246

$

(1,546)

$

$

1,700

3.67

Acquired product technology right

 

45,400

 

(5,062)

 

 

40,338

 

12.66

Acquired technology right

30,200

(946)

29,254

16.50

Acquired product distribution rights

 

11,354

 

(2,450)

 

 

8,904

 

8.35

Acquired in-process R&D

2,600

2,600

Indefinite-lived

Acquired commercial technology

630

(335)

295

0.50

Acquired trade name

400

(106)

294

1.50

Acquired customer lists

 

390

 

(390)

 

 

 

0.00

Total

$

94,220

$

(10,835)

$

$

83,385

 

13.30

June 30, 2021

Weighted-

Average

Gross

Remaining

Carrying

Accumulated

    

Net Carrying

Life (in

    

Amount

    

Amortization

    

Amount

    

years)

(In thousands)

Licensed assets

$

3,246

$

(1,430)

$

1,816

3.92

Acquired product technology right

45,400

(4,160)

41,240

12.88

Acquired technology right

30,200

(501)

29,699

16.75

Acquired product distribution rights

11,354

(2,073)

9,281

8.57

Acquired in-process R&D

 

2,600

 

 

2,600

Indefinite-lived

Acquired commercial technology

630

(178)

452

0.75

Acquired trade name

400

(56)

344

1.75

Acquired customer lists

390

(358)

32

0.01

Total

$

94,220

$

(8,756)

$

85,464

13.47

Schedule of future amortization expense

     

September 30, 

(In thousands)

2022 (remaining 9 months)

$

5,960

2023

7,489

2024

7,333

2025

7,099

2026

6,331

2027

6,301

Thereafter

40,272

Total future amortization expense

$

80,785